Acarix AB is a Sweden-based provider of diagnostic solutions for coronary artery disease (CAD). The Companyâ€™s primary product CADScor System features phonocardiography technique and algorithms. The CADScor System is fixed with a specific patch to the chest of the patient, with the recording head placed at the forth left intercostal space, and the sensor resting on the sternum. Instructions for the procedure are given on the display for the operator and audio cues guide a patient during the two-minute heart sound recording. After recording, the CAD-score is calculated, and presented on the display of the CADScor Sensor, enabling a physicians, nurses and laboratory technicians to make a rule-out diagnosis.

Employees

Sector

Advanced Medical Equipment & Technology

Calendar

11-05 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
11/09/26	SEK 0.2275	+1.56%	516,182
10/09/26	SEK 0.2240	+4.19%	797,521
09/09/26	SEK 0.2150	-2.71%	1,024,641
08/09/26	SEK 0.2210	-2.00%	1,094,664
07/09/26	SEK 0.2255	-4.04%	2,180,939

Delayed Quote Nasdaq Stockholm

More quotes

Quarterly revenue - Rate of surprise

Company calendar

Delayed Nasdaq Stockholm 11:39:15 11/09/2026 BST			5-day change	1st Jan Change
0.2275 ^SEK	+1.56%		-3.19%	-15.11%

12:07pm	Acarix Publishes Peer-Reviewed Study Confirming CADScor System Diagnoses Heart Failure With Fewer False Positives Than Standard Blood Test	CI
08-13	Acarix AB, Q2 2026 Earnings Call, Aug 13, 2026

Market Cap	278M 28.75M 24.73M 23.33M 21.26M 39.73M 2.75B 40.09M 107M 1.39B 108M 106M 4.43B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	278M 28.75M 24.73M 23.33M 21.26M 39.73M 2.75B 40.09M 107M 1.39B 108M 106M 4.43B	EV / Sales 2026 *	19.8x	EV / Sales 2027 *	8.68x
Free-Float	79.69%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	ACARIX	Delayed
OTC Markets	ACIXF	Delayed
CBOE		Real-time
Deutsche Boerse AG	7AC	Delayed
CBOE		Real-time

12:07pm	Acarix Publishes Peer-Reviewed Study Confirming CADScor System Diagnoses Heart Failure With Fewer False Positives Than Standard Blood Test	CI
08-13	Acarix AB, Q2 2026 Earnings Call, Aug 13, 2026
08-13	Acarix AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-13	Calendar for Thursday, August 13	FW
08-10	Acarix Receives Regulatory Approval For The CADScor System In The UAE	CI
08-10	Acarix Receives UAE Clearance for Point-of-Care Diagnostic Aid	MT
06-17	Acarix AB Announces Directorate Appointments	CI
06-16	Acarix AB Announces That Marlou Janssen-Counott Declines Re-Election as A Member of the Board of Directors	CI
06-12	Calendar Monday June 15 - Friday June 19	FW
05-21	Acarix AB, Q1 2026 Earnings Call, May 18, 2026
05-18	Acarix AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Calendar: Thursday, May 7	FW
04-14	Acarix AB Auditor Raises 'Going Concern' Doubt	CI

Acarix AB Share Price

Stocks

ACARIX

SE0009268717

Advanced Medical Equipment & Technology

Valuation : Acarix AB

Chart: Acarix AB

Latest news : Acarix AB

Last Transcript : Acarix AB

Analysts' recommendations : Acarix AB

Press Releases : Acarix AB

Quotes and Performance

Price Extremes

Managers and Directors : Acarix AB

Medical Diagnostic & Testing Equipment

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

08:46am	Peer-Reviewed Study Confirms CADScor System Can Diagnose Heart Failure With Far Fewer False Positives Than Standard Blood Test	AQ
08-17	Acarix (Q2 Review): Laying the groundwork	AQ
08-13	Acarix (Q2 Initial take): In line with estimates	AQ
08-13	Acarix Publishes Second Quarter and First Half 2026 Results	AQ
08-11	Acarix Receives Regulatory Approval for the CADScor(R) System in the UAE (United Arab Emirates)	AQ

1 day	+1.56%
1 week	-3.19%
Current month	-7.52%
1 month	-11.31%
3 months	-13.83%
6 months	-18.17%
Current year	-15.11%

1 week	0.2	0.24
1 month	0.2	0.26
Current year	0.2	0.33
1 year	0.2	0.35
3 years	0.17	0.6
5 years	0.17	1.58
10 years	0.17	26.8

Manager	Title	Age	Since
Aamir Mahmood CEO	Chief Executive Officer	-	31/01/2024
Christian Lindholm CEO	Chief Executive Officer	62	22/02/2018

Director	Title	Age	Since
Kenneth Nelson BRD	Director/Board Member	52	13/05/2024
Tony Das BRD	Director/Board Member	-	13/05/2024
Louise Janssen-Counotte BRD	Director/Board Member	61	31/12/2019

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ACARIX AB	+1.56%	-3.19%	-30.96%	-14.47%	28.75M
SARTORIUS AG	+0.19%	-2.32%	+19.68%	-31.41%	16.65B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+4.40%	+8.97%	-30.26%	+60.96%	1.78B
ECKERT & ZIEGLER SE	+0.85%	-2.80%	-27.00%	+24.73%	894M
QUIDELORTHO CORPORATION	-3.88%	-12.78%	-56.03%	-83.72%	833M
VAREX IMAGING CORPORATION	-0.16%	-0.27%	+68.52%	-3.25%	778M
CONTEC MEDICAL SYSTEMS CO.,LTD	-1.89%	-2.59%	-35.58%	-48.27%	654M
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	-2.22%	-4.26%	-41.91%	-46.05%	591M
REVENIO GROUP OYJ	+3.02%	-14.92%	-43.23%	-39.69%	436M
908 DEVICES INC.	-3.51%	-6.87%	+64.04%	+45.87%	386M
Average	-0.16%	-5.25%	-11.27%	-13.53%	2.3B
Weighted average by Cap.	+0.25%	-4.84%	+9.26%	-22.72%

	2026 *	2027 *
Net sales	14M 1.45M 1.25M 1.18M 1.07M 2M 139M 2.02M 5.39M 70.25M 5.44M 5.32M 223M	32M 3.31M 2.85M 2.69M 2.45M 4.58M 317M 4.62M 12.32M 161M 12.43M 12.16M 510M
Net income	-30.8M -3.19M -2.74M -2.59M -2.36M -4.4M -305M -4.44M -11.85M -155M -11.97M -11.71M -491M	-15.3M -1.58M -1.36M -1.28M -1.17M -2.19M -151M -2.21M -5.89M -76.78M -5.95M -5.82M -244M
Net Debt	-	-